Best Peptides for Fat Loss: An Evidence-Ranked Research Overview

Growth hormone secretagogues target fat through distinct pathways — some by mimicking GHRH at the pituitary, others by activating ghrelin receptors, and one by bypassing GH signaling entirely. The evidence spread is wide: one compound carries an FDA indication for visceral fat reduction in HIV lipodystrophy, while others remain confined to rodent lipolysis models with no controlled human data.

The GH Axis as a Lipolysis Target: Why Peptides Beat Exogenous Hormone

Growth hormone drives fat loss by binding hepatic GH receptors, increasing IGF-1 production, and activating hormone-sensitive lipase in adipocytes. Direct GH administration achieves this, but it also suppresses endogenous pulsatile secretion, raises fasting glucose, and carries regulatory and reconstitution burdens. Secretagogues preserve or amplify the body's natural GH pulses without replacing them — maintaining feedback loops that exogenous GH shuts down.

The distinction matters because GH pulse amplitude, not steady-state elevation, appears to drive the metabolic effects most relevant to fat oxidation. Pulsatile GH release correlates with improved insulin sensitivity in some studies, while continuous elevation can impair it. Peptides that trigger endogenous pulses therefore offer a different metabolic profile than sustained supraphysiologic dosing.

Not all peptides in this category work through GH. AOD-9604, a fragment of the hGH molecule, was engineered to retain lipolytic activity while avoiding GH receptor binding entirely. It represents a fundamentally different approach: isolating one downstream effect without activating the receptor responsible for growth, IGF-1 induction, or glucose dysregulation.

How Individual Secretagogues Differ: Receptor Affinity, Half-Life, and Non-GH Effects

The category divides along three axes: mechanism of GH release, pharmacokinetic duration, and ancillary receptor activity.

GHRH analogs — Tesamorelin, Sermorelin, Mod GRF 1-29, and CJC-1295 DAC — bind the GHRH receptor on pituitary somatotrophs. Tesamorelin and Sermorelin have plasma half-lives under 10 minutes; CJC-1295 DAC extends this to several days through a drug affinity complex that resists enzymatic degradation. The longer half-life alters the pulse pattern: CJC-1295 DAC produces sustained rather than discrete GH peaks, which may shift its metabolic effects closer to those of exogenous GH.

Ghrelin receptor agonists — GHRP-2, GHRP-6, Hexarelin, and Ipamorelin — activate the growth hormone secretagogue receptor (GHS-R1a), which triggers GH release through a pathway independent of GHRH. GHRP-6 and GHRP-2 also stimulate prolactin and cortisol at higher doses; Ipamorelin shows greater selectivity for GH without affecting these other axes. Hexarelin diverges further by binding cardiac GHS-R1a, producing cardioprotective effects in animal models that have nothing to do with GH.

Orally active GHS-R1a agonists like MK-677 extend the half-life to over 24 hours, creating tonic rather than pulsatile GH elevation. MK-677 also increases appetite and insulin resistance in longer trials — effects not consistently seen with shorter-acting secretagogues.

AOD-9604 avoids the GH receptor entirely. In rodent adipocyte studies, it activates beta-3 adrenergic receptors and stimulates lipolysis without raising IGF-1. If the mechanism translates to humans, it would represent the only compound in this category that reduces fat independently of GH pathway activation. The Phase II human data showed modest fat loss, but the trial was underpowered and the compound was never advanced.

The Evidence Landscape: One Approved Drug, Several Investigated Compounds, and Many Research-Only Peptides

Tesamorelin is the only peptide in this category with FDA approval for fat reduction. Two placebo-controlled trials in HIV patients with abdominal lipodystrophy (n=806 total) showed a mean visceral adipose tissue (VAT) reduction of 15–18% at 26 weeks, measured by CT scan. The effect was specific to VAT; subcutaneous fat did not decrease significantly. These trials enrolled a narrow population — HIV-positive adults with documented central fat accumulation on antiretrovirals — and the compound carries a black-box warning requiring screening for malignancy. It is not approved for general obesity or cosmetic fat loss.

Sermorelin was used off-label for growth hormone deficiency in children before being withdrawn from the US market in 2008 for commercial, not safety, reasons. Its lipolytic effects in adults were studied in small trials showing modest reductions in body fat percentage, but no large controlled study in a fat-loss indication exists.

CJC-1295 DAC reached Phase I/II trials for GH deficiency and showed sustained GH and IGF-1 elevation over 1–2 weeks. No published trial has formally tested it as a fat-loss intervention in humans, though one small study (n=18) in healthy men showed decreased fat mass after 60 days. Longer trials stopped before publication, and no peer-reviewed Phase III data exist.

Ipamorelin completed Phase II trials for postoperative ileus and showed GH release without cortisol or prolactin elevation, but these were not fat-loss studies. A handful of small trials in elderly adults reported modest changes in lean-to-fat ratio, but none were powered or designed to assess adipose reduction as a primary endpoint.

MK-677 has been studied in over a dozen controlled trials, mostly in elderly or GH-deficient populations. A 2-year trial in 65 older adults showed a small increase in lean mass and a trend toward fat mass reduction, but the effect was not statistically significant. MK-677 consistently increases appetite and fasting glucose, which complicates its use as a fat-loss agent.

AOD-9604 completed two Phase II obesity trials. The larger trial (n=300) showed a mean fat loss of approximately 1.1 kg more than placebo over 12 weeks — statistically significant but clinically modest. No Phase III trial was conducted, and the compound has not been developed further by any pharmaceutical entity.

The remaining compounds in this category — GHRP-2, GHRP-6, Hexarelin, Mod GRF 1-29 — have no published controlled human trials testing fat loss as a primary outcome. Their lipolytic effects are inferred from GH elevation data in small pharmacokinetic studies and from extrapolation of rodent or cell culture lipolysis assays.

Compounds in This Category

Tesamorelin is the only FDA-approved peptide for reducing visceral adipose tissue, indicated specifically for HIV-associated lipodystrophy. It binds the GHRH receptor with high affinity and triggers physiologic GH pulses without replacing endogenous secretion. The approval was based on CT-confirmed VAT reduction in two large placebo-controlled trials, making it the only compound in this category with Level 1 evidence for fat loss in a defined clinical population.

CJC-1295 DAC extends GHRH half-life from minutes to days by forming a drug affinity complex with serum albumin, which resists dipeptidyl peptidase-IV degradation. This produces sustained rather than pulsatile GH elevation, which may alter its metabolic effects relative to shorter-acting GHRH analogs. Human trials showed GH and IGF-1 increases lasting 1–2 weeks, but no published Phase III data exist for any indication, and fat-loss outcomes were not formally assessed in controlled studies.

Ipamorelin is the most selective ghrelin receptor agonist in this category, raising GH without significantly affecting cortisol, prolactin, or ACTH at standard doses. Phase II data in postoperative ileus confirmed its selectivity profile in humans, but no large trial has tested it as a fat-loss intervention. The compound's short half-life (approximately 2 hours) requires multiple daily administrations to sustain GH elevation.

MK-677 is an orally bioavailable GHS-R1a agonist with a plasma half-life exceeding 24 hours, producing tonic rather than pulsatile GH elevation. Multi-month trials in elderly adults showed small increases in lean mass and inconsistent fat reduction, but also increased fasting glucose and appetite. Its long half-life makes it convenient for research use, but the metabolic side effects complicate interpretation of fat-loss outcomes.

AOD-9604 is a 16-amino-acid fragment of human growth hormone designed to retain lipolytic activity without binding the GH receptor. In vitro studies showed beta-adrenergic activation and lipid mobilization in rodent adipocytes; Phase II human trials showed statistically significant but clinically modest fat loss. The compound was never advanced past Phase II, and no independent replication of its mechanism in human adipose tissue has been published.

Sermorelin is the shortest GHRH analog in this category, consisting of the first 29 amino acids of the 44-amino-acid native hormone. It was used clinically for pediatric GH deficiency before market withdrawal in 2008. Small studies in adults showed GH-stimulated reductions in body fat percentage, but no large controlled trial in a fat-loss indication exists, and its very short half-life (under 10 minutes) requires frequent dosing.

Mod GRF 1-29, also called CJC-1295 without DAC, is a modified version of Sermorelin with substitutions at positions 2, 8, 15, and 27 that extend half-life to approximately 30 minutes by resisting enzymatic cleavage. It produces discrete GH pulses similar to endogenous GHRH but lacks the multi-day activity of CJC-1295 DAC. No controlled human trials have assessed its fat-loss effects; its use remains confined to research settings.

GHRP-2 and GHRP-6 are first-generation ghrelin mimetics that raise GH, cortisol, and prolactin through GHS-R1a activation. GHRP-6 increases appetite more strongly than GHRP-2, which complicates fat-loss outcomes. Neither has been studied in controlled fat-loss trials; their effects are inferred from small pharmacodynamic studies showing transient GH elevation.

Hexarelin is structurally similar to GHRP-6 but shows greater potency at GHS-R1a and unique cardioprotective effects in rodent ischemia models, mediated by cardiac GHS-R1a independent of GH release. It also causes greater cortisol elevation than other GHRPs and shows rapid desensitization with repeated dosing. No human fat-loss trials exist. For research purposes only, all compounds in this category require proper handling, reconstitution, and storage protocols.

Follistatin 344 is included in some fat-loss discussions due to its myostatin-inhibiting properties, which increase lean mass in animal models. Myostatin inhibition can indirectly improve body composition by shifting the lean-to-fat ratio, but Follistatin does not act on adipocytes or GH pathways. Its inclusion in this category is mechanistically inaccurate; it belongs to muscle growth research, not lipolytic peptides.

FAQ

Q: Which peptide has the strongest human evidence for fat loss?

Tesamorelin is the only compound with Level 1 evidence from large placebo-controlled trials. It reduced visceral adipose tissue by 15–18% in HIV patients with lipodystrophy, measured by CT. No other peptide in this category has comparable human data. AOD-9604 showed statistically significant but modest fat loss in Phase II; MK-677 trials report inconsistent fat reduction and are confounded by appetite increases.

Q: Do secretagogues avoid the insulin resistance seen with exogenous growth hormone?

Not entirely. Pulsatile GH release from short-acting secretagogues like Ipamorelin and Sermorelin appears to preserve insulin sensitivity better than continuous exogenous GH in small trials, but MK-677's tonic elevation raises fasting glucose and HbA1c in longer studies. Tesamorelin, despite FDA approval, requires glucose monitoring due to potential insulin resistance. The idea that secretagogues categorically avoid GH's metabolic side effects is not supported by the data.

Q: Why isn't AOD-9604 used clinically if it avoids the GH receptor?

Phase II trials showed only ~1 kg greater fat loss than placebo over 12 weeks — statistically significant but not commercially viable. The pharmaceutical developer did not pursue Phase III, and no other entity has licensed the compound. Its receptor mechanism in humans remains partially speculative; beta-adrenergic activation was demonstrated in rodent adipocytes, but independent replication in human tissue has not been published.

Q: Can stacking a GHRH analog with a ghrelin agonist increase fat loss more than either alone?

The combination produces higher peak GH levels than either compound alone in pharmacokinetic studies, but no controlled trial has tested whether this translates to greater fat loss. The logic is mechanistically sound — GHRH and ghrelin act through separate receptors with additive effects on somatotroph activation — but stacking also increases the likelihood of side effects (elevated cortisol, glucose dysregulation) without established benefit in body composition endpoints.

Q: How do these peptides compare to GLP-1 agonists for fat loss?

GLP-1 agonists (semaglutide, tirzepatide) produce mean fat loss of 10–20% of body weight in obesity trials through appetite suppression and insulin sensitization — far larger than any secretagogue has demonstrated. Tesamorelin's 15–18% VAT reduction in HIV lipodystrophy is comparable in magnitude but specific to visceral fat and a narrow population. For general obesity, the evidence strongly favors GLP-1 agonists over GH secretagogues.

---

The information provided here is intended for educational and research purposes. These compounds are not approved for fat loss outside specific indications, and their use should occur only under appropriate supervision in formal research settings. Always consult a qualified healthcare provider before considering any research compound.